A novel transport and delivery mechanism underpins the effectiveness of prolyl-m-sarcolysyl-p-fluorophenylalanine (PSF) in a human melanoma xenograft nude-mouse model

Pigment Cell and Melanoma Research

Volumn 21, Issue 4, 2008, Pages 439-450

  Dierickx, Karen M E ^a   Morandini, Renato ^a   Nguyen, Thi Hien ^a   Salès, François ^a   Kauffmann, Jean Michel ^b   Ghanem, Ghanem E ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Alkylating agents; Drug targeting and delivery; Human melanoma bearing nude mice; Melphalan; PSF; Tumor associated proteases

Indexed keywords

ALKYLATING AGENT; CYCLOPHOSPHAMIDE; DRUG METABOLITE; MELPHALAN; METALLOPROTEINASE; PROLYL 3 SARCOLYSYL 4 FLUOROPHENYLALANINE; PROTEINASE; SARCOLYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CONTROLLED STUDY; CYTOTOXICITY; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG STABILITY; DRUG TRANSPORT; ERYTHROCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; MELANOMA; MOUSE; NONHUMAN; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALIA; MUS MUSCULUS;

EID: 47249108628     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2008.00471.x     Document Type: Article

References (44)

1. Albright, C.F., Graciani, N., Han, W. et al. (2005). Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. Mol Cancer Ther. 4, 751 760.
2. Ardizzoni, A., Antonelli, G., Ricci, S. et al. (2000). Ambamustine in the second-line treatment of patients with small-cell lung cancer: a phase II Fonicap study. Am. J. Clin. Oncol. 23, 22 25.
3. Baker, A.H., Edwards, D.R. Murphy, G. (2002). Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 115, 3719 3727.
4. Becker, J.C., Kirkwood, J.M., Agarwala, S.S., Dummer, R., Schrama, D. Hauschild, A. (2006). Molecularly targeted therapy for melanoma: current reality and future options. Cancer 107, 2317 2327.
5. Biroccio, A., Benassi, B., Fiorentino, F. Zupi, G. (2004). Glutatione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents. Neoplasia 6, 195 206.
6. Carmichael, J., DeGraff, W.G., Gazdar, A.F., Minna, J.D. Mitchell, J.B. (1987). Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47, 936 942.
7. Chung, D. Kratz, F. (2006). Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA). Bioorg. Med. Chem. Lett. 16, 5157 5163.
8. De Barbieri, A. (1972). Peptichemio: a synthesis of pharmacological, biochemical and biomolecular investigations. In Proceedings of the Symposium on Peptichemio, A. De Barbieri, ed Milan : Italy pp. 4 46.
9. De Barbieri, A., Dall'Asta, L., Comini, A., Spingolo, V., Mosconi, P. Coppi, G. (1983). Synthesis, acute toxicity and chemotherapeutic anti-cancer activities of a new tripeptidic mustard. Il Farmaco-Ed Sc. 38, 205 218.
10. Ehrsson, H., Lewensohn, R., Wallin, I., Hellström, M., Merlini, G. Johansson, B. (1993). Pharmacokinetics of peptichemio in myeloma patients: release of m-l-sarcolysin in vivo and in vitro. Cancer Chemother. Pharmacol. 31, 265 268.
11. Ferrier, C.M., van Muijen, G.N. Ruiter, D.J. (1998). Proteases in cutaneous melanoma. Ann. Med. 30, 431 442.
12. Furrer, M., Altermatt, H.J., Ris, H.B., Althaus, U., Ruegg, C., Lienard, D. Lejeune, F.J. (1997). Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system. Melanoma Res. 7, S43 S49.
13. Grubbs, E.G., Ueno, T., Abdel-Wahab, O., Cheng, T.Y., Pruitt, S.K., Colvin, O.M., Friedman, H.S. Tyler, D.S. (2004). Modulation of regional chemotherapy in the extremity melanoma model. Surgery 136, 210 218.
14. Gullbo, J., Dhar, S., Luthman, K., Ehrsson, H., Lewensohn, R., Nygren, P. Larsson, R. (2003a). Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L- sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan. Anticancer Drugs 14, 617 624.
15. Gullbo, J., Wickström, M., Tullberg, M., Ehrsson, H., Lewensohn, R., Nygren, P., Luthman, K. Larsson, R. (2003b). Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1. J. Drug Target. 11, 355 363.
16. Gullbo, J., Wallinder, C., Tullberg, M., Lovborg, H., Ehrsson, H., Lewensohn, R., Nygren, P., Luthman, K. Larsson, R. (2003c). Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L- fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2. Mol. Cancer Ther. 2, 1331 1339.
17. Gullbo, J., Lindhagen, E., Bashir-Hassan, S., Tullberg, M., Ehrsson, H., Lewensohn, R., Nygren, P., De La Torre, M., Luthman, K. Larsson, R. (2004). Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo. Invest New Drug. 22, 411 420.
18. Hansson, J., Lewensohn, R. Ringborg, U. (1991). Cytotoxicity and DNA cross-linking induced by peptide conjugated m-L-sarcolysin in human melanoma cells. Anticancer Res. 11, 1725 1730.
19. Hofmann, U.B., Houben, R., Bröcker, B.B. Becker, J.C. (2005). Role of matrix metalloproteinases in melanoma cell invasion. Biochemie 87, 307 314.
20. Ishida, T., Takanashi, Y. Kiwada, H. (2006). Safe and efficient drug delivery system with liposomes for intrathecal application of an antivasospastic drug, fasudil. Biol. Pharm. Bull. 29, 397 402.
21. Jadhav, K.R., Shaikh, I.M., Ambade, K.W. Kadam, V.J. (2006). Applications of microemulsion based drug delivery system. Curr Drug Deliv. 3, 267 273.
22. Jiang, J.D., Zhang, H., Li, J.N., Roboz, J., Qiao, W.B., Holland, J.F. Bekesi, G. (2001). High anticancer efficacy of L-proline-m-bis (2-chloroethyl) amino-L-phenylalanyl-L-norvaline ethyl ester hydrochloride (MF13) in vivo. Anticancer Res. 21, 1681 1689.
23. Kupczyk-Subotkowska, L., Tamura, K., Pal, D., Sakaeda, T., Siahaan, T.J., Stella, V.J. Borchardt, R.T. (1997). Derivatives of melphalan designed to enhance drug accumulation in cancer cells. J. Drug Target. 4, 359 370.
24. La Porta, C.A. (2007). Drug resistance in melanoma: new perspectives. Curr Med Chem. 14, 387 391.
25. Larsson, R., Dhar, S., Ehrsson, H., Nygren, P. Lewensohn, R. (1998). Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl- L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients. Br. J. Cancer 78, 328 335.
26. Legha, S.S., Ajani, J.A., Blumenschein, G.R., Hortobagyi, G.N. Buzdar, A.U. (1994). Combination chemotherapy of metastatic breast carcinoma with cyclophasphamide, adriamycin and peptichemio. Cancer 53, 1836 1840.
27. Lewensohn, R., Ehrsson, H., Hansson, J. Ringborg, U. (1991). Increased toxicity and DNA cross-linking by peptide bound m-L-sarcolysin (Peptichemio) as compared to melphalan and m-L-sarcolysin in human melanoma cell lines. Anticancer Res. 11, 321 324.
28. Mansour, A.M., Drevs, J., Esser, N., Hamada, F.M., Badary, O.A., Unger, C., Fichtner, I. Kratz, F. (2003). A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res. 63, 4062 4066.
29. Mittal, S., Tsume, Y., Landowski, C.P., Lee, K.D., Hilfinger, J.M. Amidon, G.L. (2007). Proline prodrug of melphalan, prophalan-L, demonstrates high therapeutic index in a murine melanoma model. Eur. J. Pharm. BioPharm 67, 752 758.
30. Okrój, M., Stawikowskal, D., Słomińska, E.M., Myśliwski, A. Bigda, J. (2006). The atypical pattern of cell death in B16F10 melanoma cells treated with TNP-470. Cell Mol. Biol. Lett. 11, 384 395.
31. Paccagnella, A., Tredese, F., Salvagno, L. et al. (1985). Peptichemio in pre-treated patients with ovarian cancer. Cancer Treat Rep. 69, 17 20.
32. Paukner, S., Stiedl, T., Kudela, P., Bizik, J., Al Laham, F. Lubitz, W. (2006). Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery. Expert Opin. Drug Deliv. 3, 11 22.
33. Pfuhler, S. Wolf, H.U. (1996). Detection of DNA-crosslinking agents with the alkaline comet assay. Environ. Mol. Mutagen. 27, 196 201.
34. Roboz, J., Jiang, J., Holland, J.F. Bekesi, G. (1997). Selective tumor apoptosis by MF13, L-Prolyl-L-m-[bis(chloroethyl)amino]-phenylalanyl-L-norvaline ethyl ester, a new sarcolysin containing tripeptide. Cancer Res. 57, 4795 4802.
35. Rossi, C.R., Foletto, M., Pilati, P., Mocellin, S. Lise, M. (2002). Isolated limb perfusion in locally advanced cutaneous melanoma. Semin. Oncol. 29, 400 409.
36. Springolo, V., Borella, F., Finardi, G.P., Gatti, M.T. Coppi, G. (1989). High-performance liquid chromatographic determination of m-bis(chloroethyl)- aminophenyl-L-alanine in plasma. J. Chromatogr. 490, 224 229.
37. Taetle, R., Rosen, F., Abramson, I., Venditti, J. Howell, S. (1987). Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts. Cancer Treat Rep. 71, 297 304.
38. Tawbi, H.A. Kirkwood, J.M. (2007). Management of metastatic melanoma. Semin. Oncol. 34, 532 545.
39. Tomayko, M.M. Reynolds, C.P. (1989). Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 24, 148 154.
40. Tura, S., Mazza, P., Gherlinzoni, F. et al. (1989). Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non Hodgkin's lymphomas. Cancer Chemother. Pharmacol. 23, 123 125.
41. Verlicchi, F., Boschi, S., Visani, G., Guidi, A., Tosi, P., Cavo, M. Tura, S. (1990). Evidence for increased intracellular transport of m-sarcolysine (alkylating moiety) when combined with two amino acid analogs (PTT-119). Blut. 61, 311 313.
42. Wickström, M., Johnsen, J.I., Ponthan, F. et al. (2007). The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo. Mol cancer ther. 6, 2409 2417.
43. Yagi, M.J., Zanjani, M., Holland, J.F. Bekesi, J.G. (1984). Increased cancericidal activity of PTT-119; a new synthetic bis-(2-chloroethyl)amino-L- phenylalanine derivative with carrier amino acids. II. In vivo bioassay. Cancer Chemother. Pharmacol. 12, 77 82.
44. Yu, D., Fukuda, T., Tuoya, Kuroda, S., Tanizawa, K., Kondo, A., Ueda, M., Yamada, T., Tada, H. Seno, M. (2006). Engineered bio-nano capsules, the selective vector for drug delivery system. IUBMB Life 58, 1 6.